Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities: 2017-2018

  • Crinetics Pharmaceuticals' Preferred Stock Liabilities was N/A to $93.0 million in Q2 2018 from the same period last year, while for Jun 2018 it was $93.0 million, marking a year-over-year change of. This contributed to the annual value of $29.7 million for FY2017, which is N/A change from last year.
  • According to the latest figures from Q2 2018, Crinetics Pharmaceuticals' Preferred Stock Liabilities is $93.0 million, which was up 213.05% from $29.7 million recorded in Q4 2017.
  • Crinetics Pharmaceuticals' Preferred Stock Liabilities' 5-year high stood at $93.0 million during Q2 2018, with a 5-year trough of $29.7 million in Q4 2017.
  • Its 2-year average for Preferred Stock Liabilities is $61.3 million, with a median of $61.3 million in 2017.